Loading company…
ZSKY develops individualized dendritic cell tumor vaccines and systems for identifying tumor neoantigens.
Founded in 2018 and based in Beijing, ZSKY researches and develops individualized dendritic cell tumor vaccines. It built AI-based systems to predict and validate tumor neoantigens, and has vaccine candidates in clinical trials for brain, intestinal, liver, bile duct, and pancreatic cancers. In November 2020, it closed a pre-Series A round led by Harmony Venture, with Gongqingcheng Pengbo Investment Management, Leimerious, and Sichuan Development Holding participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in